Keyphrases
HIV Patients
77%
AIDS/HIV
34%
Community-acquired Pneumonia
31%
Antiretroviral Therapy
30%
Confidence Interval
27%
Streptococcus Pneumoniae
23%
Adult Patients
23%
Risk Factors
20%
Highly Active Antiretroviral Therapy (HAART)
20%
Clinical Outcomes
20%
Invasive Pneumococcal Disease
20%
Co-infected Patients
19%
Clinical Presentation
19%
Infected Patients
15%
Pneumococcal Serotypes
15%
Antiretroviral
15%
HIV-1 Infection
14%
High-grade Anal Intraepithelial Neoplasia
14%
Ribavirin
12%
Tuberculosis
12%
Visceral Leishmaniasis
11%
HIV RNA
11%
Darunavir
11%
Spain
10%
HIV-infected MSM
10%
Drug-resistant HIV
10%
Pneumocystis Jirovecii
10%
Etiology
10%
Hepatitis C Virus
9%
Virological Failure
9%
Immune Reconstitution
9%
Odds Ratio
8%
Human Immunodeficiency Virus Type 1 (HIV-1)
8%
Clinical Trials
8%
Hospitalized Patients
8%
Immune Response
8%
HIV-infected Adults
8%
Ritonavir
8%
Resistance mutations
8%
Respiratory Failure
8%
Leishmania
7%
T Cells
7%
Viral Reactivation
7%
Observational Cohort Study
7%
CD4 Count
7%
Urine Samples
7%
Respiratory Secretions
7%
Pneumococcal Vaccination
7%
HIV Infection
7%
Tenofovir
7%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Community-Acquired Pneumonia
19%
Serotype
17%
Pneumococcal Infection
16%
Anus Carcinoma
14%
Pneumococcal Pneumonia
14%
Streptococcus Pneumonia
14%
Infection
12%
Antiretroviral Therapy
11%
Respiratory Failure
11%
Human Immunodeficiency Virus 1 Infection
10%
Visceral Leishmaniasis
10%
Human Immunodeficiency Virus Infection
10%
Pneumococcus Vaccine
9%
Clinical Trial
9%
Immune Reconstitution Inflammatory Syndrome
8%
Patient with Human Immunodeficiency Virus
8%
Nucleoside
7%
Cohort Study
7%
Secretion (Process)
7%
Observational Study
7%
Fulguration
7%
Darunavir
7%
Spondylitis
7%
Pneumocystis Jirovecii
7%
Salvage Therapy
7%
Organizing Pneumonia
7%
Empyema
7%
Septic Shock
7%
Lactic Acidosis
7%
Reverse-Transcriptase Inhibitor
7%
Diseases
6%
Hepatitis C Virus
6%
Virus Infection
6%
Intensive Care Unit
6%
Urine Sampling
6%
Cell Count
5%
Prospective Cohort Study
5%
Cohort Effect
5%
Antimicrobial Therapy
5%
Odds Ratio
5%
Urinary System
5%
Infective Endocarditis
5%
Comorbidity
5%
Highly Active Antiretroviral Therapy
5%
Recurrent Disease
5%
Polymerase Chain Reaction
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
83%
Pneumococcal Infection
15%
Hepatitis C Virus
15%
Clinical Trial
13%
Streptococcus Pneumonia
13%
Tenofovir
11%
Ritonavir
10%
Infection
10%
Ribavirin
9%
Darunavir
9%
Pneumococcus Vaccine
8%
Human Immunodeficiency Virus Infection
8%
Proteinase Inhibitor
8%
Nucleoside
7%
Community Acquired Pneumonia
7%
Disease
7%
Human Immunodeficiency Virus 1 Infection
7%
Hospital Acquired Pneumonia
7%
Lactic Acidosis
7%
Visceral Leishmaniasis
7%
RNA Directed DNA Polymerase Inhibitor
7%
Lamivudine
6%
Abacavir
6%
Azithromycin
6%
Levofloxacin
6%
Macrolide
5%
Antibiotics
5%
Mitochondrial DNA
5%
Emtricitabine
5%
Observational Study
5%
Mortality Rate
5%
Comorbidity
5%
Cohort Study
5%